Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.
Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, Savic S, Harbeck N, Nitz U, Gluz O, von Bergwelt-Baildon M, Kreipe H, Reddy S, Christgen M, Zippelius A.
Müller P, et al.
Sci Transl Med. 2015 Nov 25;7(315):315ra188. doi: 10.1126/scitranslmed.aac4925.
Sci Transl Med. 2015.
PMID: 26606967